Octave Bioscience

Octave Bioscience is a private, commercial-stage diagnostics company pioneering a data-driven approach to managing multiple sclerosis. Its core innovation is the MSDA Test, a blood-based biomarker panel that provides objective, personalized insights into disease activity, aiming to inform treatment decisions and improve patient care. The company is leveraging its platform and partnerships to establish its test in clinical practice while expanding its pipeline to include assessments for MS disease progression and Parkinson's disease. With a focus on scientific validation and real-world utility, Octave is positioning itself at the intersection of neuroscience, diagnostics, and data analytics.

Proprietary multi-omics biomarker discovery and validation platform integrating proteomics, data science, and machine learning to develop blood-based diagnostic tests for neurodegenerative diseases.

Octave competes with other companies developing blood-based biomarkers for MS, notably those focused on single markers like neurofilament light chain (e.g., Quanterix, Siemens Healthineers). It also competes with the standard of care (clinical exams and MRI) and other emerging multi-omic approaches. Its first-mover advantage with a clinically validated multi-protein panel is a key differentiator.